The effect of cynaropicrin, a sesquiterpene lactone, on the migratory properties of triple-negative breast cancer cells and the underlying mechanisms

TL;DR

This study shows that cynaropicrin, a natural compound, can reduce the spread of triple-negative breast cancer by inhibiting cell migration and key cancer-related proteins.

Contribution

The study reveals cynaropicrin's anti-metastatic and anti-angiogenic effects in triple-negative breast cancer cells.

Findings

Cynaropicrin reduced the proliferation and migration of TNBC cell lines in a concentration-dependent manner.

The compound upregulated E-cadherin and downregulated EMT and pro-angiogenic proteins like VEGFA.

These effects suggest cynaropicrin inhibits metastasis and angiogenesis in TNBC.

Abstract

Triple-negative breast cancer (TNBC) is the most metastatic type of breast cancer. Cynaropicrin, a sesquiterpene lactone, shows potential anticancer effects. This study evaluated cynaropicrin's impact on metastasis and angiogenesis in TNBC cells.

MDA-MB-231 and MDA-MB-468 cell lines were exposed to incrementing concentrations of cynaropicrin. The proliferation of the cell lines was assayed using the MTT method. A wound scratch technique was chosen to appraise the migratory properties of cells following cynaropicrin treatment. The transcript levels of epithelial-mesenchymal transition (EMT) and pro-angiogenic factors were quantified via quantitative polymerase chain reaction. The western blotting technique estimated the amount of E-cadherin, N-cadherin, Fibronectin, Vimentin, and VEGFA.

The proliferation of MDA-MB-231 and MDA-MB-468 cells was significantly lowered due to cynaropicrin in a concentration-associated way. Results of the wound healing method uncovered that cynaropicrin could mitigate the migration of breast-derived MDA-MB-231 and MDA-MB-468 cells. Cynaropicrin also upregulated E-cadherin and hindered the protein expression of N-cadherin, Vimentin, Fibronectin 1, and VEGFA in breast-derived MDA-MB-468 and MDA-MB-231 cells.

The present findings indicated the anti-metastatic capacity of cynaropicrin against TNBC by a mechanism that implicated the inhibition of the EMT and pro-angiogenic factor VEGFA. These outcomes suggest cynaropicrin as an anti-metastatic and anti-angiogenic sesquiterpene lactone against TNBC.

Figures